Biognosys, a frontrunner in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a pioneer in precision proteomics for early disease detection, have forged a strategic alliance to propel scientific exploration in biofluid proteomics biomarkers. This collaboration amalgamates Biognosys’ prowess in impartial discovery via data independent acquisition mass spectrometry (DIA-MS) with Alamar’s state-of-the-art immunoassays, fostering a holistic understanding of biomarkers.

The joint presentation at the American Society for Cancer Research (AACR) 2024 Annual Meeting in San Diego spotlighted findings from a collaborative study targeting Non-Small Cell Lung Cancer (NSCLC). Utilizing Biognosys’ TrueDiscovery® platform and Alamar’s NULISAseq™ Inflammation Panel 250, plasma samples from NSCLC patients underwent comprehensive analysis, showcasing the synergistic insights gleaned from mass spectrometry and affinity-based assays.

Capitalizing on this successful endeavor, Biognosys and Alamar are poised to deepen their collaboration both commercially and scientifically. Biognosys will extend NULISA assays from its Swiss facility, empowering precise quantification of low abundance proteins crucial in disease contexts. Meanwhile, a joint research venture will unravel the intricacies of plasma biology, leveraging Biognosys’ unbiased discovery techniques alongside Alamar’s ultra-sensitive assays to comprehensively map the plasma proteome.

Oliver Rinner, Ph.D., Founder and CEO of Biognosys, lauded the partnership as a catalyst for proteomics research advancement, envisioning a comprehensive analysis of over 5,000 proteins alongside panels of well-characterized cytokines using NULISA assays. Yuling Luo, Ph.D., Chairman, Founder, and CEO of Alamar, echoed this sentiment, emphasizing the enrichment of proteomic insights from discovery to clinical research.

This collaboration underscores both entities' dedication to scientific excellence and their joint pursuit of revolutionizing precision medicine through innovative methodologies, marking a pivotal stride in the realm of proteomics-driven diagnostics and therapeutics.